Thermo Fisher Expands U.S. Drug Manufacturing With Sanofi Ridgefield Site Acquisition

Thermo Fisher Scientific Inc. announced the completion of its acquisition of Sanofi’s sterile fill-finish and packaging site in Ridgefield, New Jersey, expanding the companies’ strategic partnership to strengthen U.S.-based drug product manufacturing. Financial terms of the transaction were not disclosed. The site will operate under Thermo Fisher’s pharma services business within its Laboratory Products and Biopharma Services segment.

“We are excited to add Sanofi’s Ridgefield site to our network and welcome more than 200 highly experienced colleagues to Thermo Fisher. Bringing this world-class facility and team into our network strengthens our U.S. manufacturing capabilities to better support pharmaceutical and biotech customers, while positioning us for future expansion,” said Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher. 

As part of the agreement, Thermo Fisher will continue producing Sanofi’s therapies at the Ridgefield facility while also opening the site to serve a broader set of pharma and biotech customers. This move addresses the increasing demand for domestic manufacturing capacity in the United States, particularly in sterile drug product supply.

With the addition of Ridgefield, Thermo Fisher enhances its global sterile fill-finish network, which already includes U.S. sites in Greenville, North Carolina, and Plainville, Massachusetts. Together, these facilities support the company’s Accelerator™ Drug Development 360° CDMO and CRO platform, helping emerging biotech and biopharma firms accelerate the delivery of life-changing medicines to patients.